Arovella Therapeutics LimitedASX: ALA

AGM FY20 Presentation

· Issued by Arovella Therapeutics Limited

Filed with ASX · · 14 pages · English

Expansion: Actively seeking new deal flow for technologies with a focus on oncology and the central nervous system ▪ Unique Platform Technology – OroMist™: Reformulate existing billion-dollar drugs for oral delivery, faster path to market, which can create cost and time savings ▪ TGA Approval Secured for ZolpiMist: ZolpiMist received TGA approval July 2020 for the treatment of short-term insomnia

Arovella Therapeutics Limited on 6ix

Earlier from Arovella Therapeutics

Later from Arovella Therapeutics

All Arovella Therapeutics news releases